Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
15.14B
Market cap15.14B
Price-Earnings ratio
26.82
Price-Earnings ratio26.82
Dividend yield
Dividend yield
Average volume
461.06K
Average volume461.06K
High today
$252.46
High today$252.46
Low today
$243.34
Low today$243.34
Open price
$252.46
Open price$252.46
Volume
504.63K
Volume504.63K
52 Week high
$282.15
52 Week high$282.15
52 Week low
$173.33
52 Week low$173.33

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $243.91, giving the company a market capitalization of 15.14B. It carries a P/E multiple of 26.82.

During the trading session on 2026-08-01, Ascendis Pharma A/S(ASND) shares reached a daily high of $252.46 and a low of $243.34. At a current price of $243.91, the stock is +0.2% higher than the low and still -3.4% under the high.

Trading activity shows a volume of 504.63K, compared to an average daily volume of 461.06K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $173.33.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $173.33.

ASND News

Simply Wall St 3d
Ascendis Pharma Could Be 17% Below Fair Value Following Its TransCon Narrative

Ascendis Pharma (NasdaqGS:ASND) has drawn fresh investor attention after recent trading left the stock around $254.44, with short term returns mixed over the pa...

Ascendis Pharma Could Be 17% Below Fair Value Following Its TransCon Narrative
TipRanks 4d
Ascendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth Hopes

Ascendis Pharma A/S (ASND) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more con...

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.